帕利哌酮缓释片与利培酮治疗精神分裂症阴性症状的对照研究

目的:探讨帕利哌酮缓释片与利培酮对精神分裂症阴性症状的疗效和安全性。方法:分别使用帕利哌酮缓释片与利培酮对60例以阴性症状为主精神分裂症患者治疗8周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)分别在治疗前、治疗第4周和第8周末评定疗效和安全性。结果:研究组显效率和有效率分别为63.3%和80%,对照组分别为60%和76.7%,两组比较,差异无统计学意义(P>0.05)。两组PANSS评分治疗后均较治疗前明显下降(P<0.05),研究组阴性症状因子分在治疗4周和8周时分别为(15.40±1.04)分和(12.80±0.76)分,显著低于对照组的(20.60±1.13)分和(18.10±0.71)分,两组比较,差异有统计学意义(P<0.05);研究组第8周末PANSS总分为(42.90±0.84)分,低于对照组的(44.80±0.61)分,有统计学差异(P<0.05)。研究组的不良反应以锥体外系反应和嗜睡为主,对照组以锥体外系反应和失眠、体重增加和视物模糊为主,两组的不良反应相当,均未见严重不良反应。结论:帕利哌酮缓释片是一种安全有效的抗精神病药,能够显著改善精神分裂症的阴性症状。

Control study of paliperidone extended-release tablet and risperidone on negative symptoms of schizophrenia

AIM: To study the efficacy and safety of paliperidone extended-release tablet(Paliperidone-ER) and Risperidone on negative symptoms of schizophrenia. METHODS: Sixty cases of schizophrenics with prominent negative symptoms were randomly divided into study group(n=30)and control group(n=30).Thirty cases of Paliperidone-ER treated patients were compared with thirty cases of Risperidone treated patients.The duration of study was 8 weeks.The therapeutic efficacy and safety were assessed with the PANSS and TESS,r...